Arikayce® (amikacin liposome inhalation suspension) approved by japan's ministry of health, labour and welfare for the treatment of patients with ntm lung disease caused by mac who did not sufficiently respond to prior treatment with mdr

Bridgewater, n.j., march 23, 2021 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that japan's ministry of health, labour and welfare (mhlw) has approved arikayce® (amikacin liposome inhalation suspension) for the treatment of patients with nontuberculous mycobacterial (ntm) lung disease caused by mycobacterium avium complex (mac) who did not sufficiently respond to prior treatment with a multidrug regimen (mdr).
INSM Ratings Summary
INSM Quant Ranking